🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

964 results for “Advanced” Clear

  1. A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

    Pharma Mar S.A.

    Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults

    phase 2 other active

    1 trial

  2. A Phase 1/2, Umbrella Study of the Efficacy and Safety of Pembrolizumab plus Enfortumab vedotin +/- Investigational Agents in First-Line metastatic urothelial carcinoma

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 other active

    1 trial

  3. A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors

    Centessa Pharmaceuticals plc

    Advanced solid tumors

    phase 2 other active

    1 trial

  4. A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors

    GlaxoSmithKline Biologicals S.A.

    Gastrointestinal Neoplasms

    phase 2 other active

    1 trial

  5. A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

    GlaxoSmithKline Biologicals S.A.

    Ovarian Neoplasms

    phase 2 other active

    1 trial

  6. A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with HER2Positive Advanced Breast Cancer

    phase 2 other active

    1 trial

  7. A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Roche Registration Limited

    Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 other active

    1 trial

  8. A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed‑Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid Tumors

    Roche Registration Limited

    Solid Tumors

    phase 2 other active

    1 trial

  9. A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    Roche Registration Limited

    Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  10. A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Advanced hepatocellular carcinoma

    phase 2 other active

    1 trial

  11. A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations

    Pierre Fabre Medicament

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 other active

    1 trial

  12. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda Pharmaceuticals International AG

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  13. ADCETRIS 50 mg powder for concentrate for solution for infusion, DACARBAZINE , DOXORUBICIN , DEXAMETHASONE , VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE

    Cancer Prevention Pharma (Ireland) Limited

    Advanced stage Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  14. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  15. ALPELISIB, FULVESTRANT, ALPELISIB, LETROZOLE, LEUPRORELIN ACETATE, GOSERELIN

    Novartis Ophthalmics Europe

    Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer

    phase 2 small molecule active

    1 trial

  16. ALPELISIB, RIBOCICLIB, LETROZOLE, LEE011, ALPELISIB, LEE011

    Novartis Ophthalmics Europe

    Advanced HR+ breast cancer

    phase 2 small molecule active

    1 trial

  17. AMG 193, AMG 193, AMG 193

    Amgen Technology (Ireland) UC

    Advanced MTAP-null solid tumors

    phase 2 small molecule active

    1 trial

  18. AMG 193, IDE397, AMG 193, IDE397, AMG 193

    Amgen Technology (Ireland) UC

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. AMG 706

    Takeda Pharmaceuticals International AG

    Advanced Gastrointestinal Stromal Tumor

    phase 2 small molecule completed

    1 trial

  20. ART0380, ART0380, GEMCITABINE , ART0380, IRINOTECAN , ART0380

    Pharma Mar S.A.

    Advanced or Metastatic Solid Tumours

    phase 2 small molecule active

    1 trial

  21. ASP1570, ASP1570, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Astellas Pharma GmbH

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  22. ASP8951, Calcium Folinate 10 mg/ml Injection, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Fluorouracil 50mg/ml Injection., OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.

    Astellas Pharma GmbH

    Advanced cancer of the stomach or the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  23. ATRN-119

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  24. AZACITIDINE

    Blueprint Medicines (Netherlands) B.V.

    Advanced Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources